Compare FMC Corp (FMC) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? FMC Corp trades at $8.05 (market cap $1.26B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: FMC Corp is the larger of the two by market cap, and FMC Corp pays a 3.96% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold FMC Corp for 68 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| FMC | MRVI | |
|---|---|---|
Market Cap | $1.26B | $977.37M |
Volume | 3,029,236 | 2,742,564 |
Sector | Basic Materials | Health |
52-Week High | $30.63 | $9.00 |
52-Week Low | $8.09 | $2.83 |
Typical Hold Time | 68 Days | 0 Days |
Enterprise Value | $5.06B | $1.08B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FMC stock trades at $8.31, down slightly by 0.12% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $2.24 billion in 2025, with negative profit margins and ROE, though recent quarterly EPS beat estimates. Analyst consensus is mixed with a price target of $14.20, and recent news highlights regulatory progress for its herbicide in Brazil and a minority equity investment by Tessenderlo Group.
The outlook remains challenged by high debt and cyclical industry headwinds, but aggressive deleveraging efforts and new product filings offer potential upside. Key risks include persistent losses, volatile cash flows, and competitive pressures in the agricultural sector, requiring careful monitoring of earnings recovery and debt reduction progress.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
